Harrington Discovery Institute (HDI) and Takeda Pharmaceuticals have teamed up to support the translation of research into treatments for rare diseases. The alliance builds on HDI’s model and results in a dedicated rare-disease funding track that will benefit from Takeda’s capabilities. Takeda is also a strategic partner of BioMotiv.

Click here to read more.